Skip to contentE
Emergent BioSolutions Inc.
E
EBSEmergent BioSolutions Inc. Q2 2020 · 10-Q
Revenue$394.70M$394.70M+62.3% vs Q2 2019 Net Income$92.70M$92.70MN/M vs Q2 2019 EPS Diluted$1.73$1.73N/M vs Q2 2019 Operating Income$126,000,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Emergent BioSolutions Inc. · CIK 1367644 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$92,800,000N/M Margins · derivedOperating margin31.9%+34.8 pt vs Q2 2019
Net margin23.5%+27.4 pt vs Q2 2019
ended Jun 30, 2020 · filed Jul 31, 2020 · 31 d after period end